RNA Therapeutics Inc. has received a written response from the FDA to its pre-IND application questions regarding the development of its lead asset, RNAT-89 (BLA-761423), an mRNA LNP formulation to express darbepoetin.
Thyroid hormones are involved in growth, development and metabolism processes. The thyroid hormone receptor β (THRβ) isoform, mainly expressed in the liver, is responsible for the reduction of cholesterol levels and thus is considered a therapeutic target for the treatment of dyslipidemia, obesity and related disorders.
Cumulus Oncology Ltd. has announced key milestones, in partnership with collaborator Leadxpro AG, in the companies’ protein structure-driven GPR68 drug discovery project.
Human rhinoviruses (hRVs) are associated with upper respiratory tract infections such as the common cold, otitis media or sinusitis. In immunocompromised individuals or older people, hRVs can exacerbate existing pulmonary conditions such as asthma or chronic obstructive pulmonary disease.
Prior work has unveiled increased levels of inosine monophosphate dehydrogenase 2 (IMPDH2) expression correlating with tumor progression and poor prognosis in several diseases. A team of researchers in China have now aimed to study IMPDH2’s role in hepatoblastoma.
“There are hundreds of strains of bird flu, and most of them don’t infect humans, or even mammals,” Stephen Cusack told BioWorld. “There are two main reasons for that.” To be able to cause an infection, a virus “has to be able to get into the cell, and for that it needs a receptor,” Cusack said. For influenza viruses, those receptors are hemagglutinin receptors, and they differ in subtle but important ways between birds and mammals.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.
Shenzhen Crystalo Biopharma Technology Co. Ltd. has divulged short transient receptor potential channel 5 (TRPC5) antagonists reported to be useful for the treatment of anxiety, depression, post-traumatic stress, diabetic nephropathy and focal segmental glomerulosclerosis.
Boehringer Ingelheim Pharma GmbH & Co KG has identified drug conjugates acting as neuromedin U receptor 2 (NMU2) agonists reported to be useful for the treatment of obesity.
Gwangju Institute of Science & Technology has synthesized compounds reported to be useful for the treatment of atopic dermatitis and inflammatory bowel disease.
RSS
